MOTS-c
NOT FDA APPROVEDMitochondrial-derived peptide
Also known as: mitochondrial-derived peptide
Not FDA approved. Sold as a research chemical, labelled not for human consumption.
Early evidence, mostly unproven in humans
- Regulatory standing. Sold as a research chemical, not approved
- Animal / preclinical only. Evidence is largely animal or in-vitro
- Registered human trials. 5 registered studies on ClinicalTrials.gov, most advanced Phase 2
- 1 cited source. Cited references provided
A read on the weight of evidence and regulatory standing behind this compound. It is not a safety score, not a purity or quality rating, and not medical advice. It is not a claim that this compound treats, cures, or prevents any condition, and not an endorsement or a recommendation to buy or use it. A low score means the evidence is thin — not that a product is unsafe; a high score means the evidence is strong — not that anyone should take it. PLOBT is independent and takes no money from any vendor; no company can pay to change this score.
Proven: strong and genuinely interesting preclinical data as an 'exercise-mimetic' with metabolic benefits in animals. NOT proven: benefits in humans. Human clinical evidence is minimal.
What it is
A peptide encoded in mitochondrial DNA that influences metabolism and insulin sensitivity; studied as an exercise-mimetic.
What the research says
Compelling animal data on metabolism and insulin sensitivity. Human data is minimal.
Published literature
Live from Europe PMC. Peer-reviewed papers discussing MOTS-c in their title or abstract, most-cited first. This is how much has been published — not how much is proven in humans. It counts landmark trials, animal studies and reviews alike.
The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance.
The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress.
MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis.
MOTS-c: A novel mitochondrial-derived peptide regulating muscle and fat metabolism.
Registered human trials
Live from ClinicalTrials.gov, the US NIH registry of human studies, refreshed daily. Counts studies where MOTS-c is the intervention being tested.
MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity
Comparison of the Effects of General Anesthesia and Combined Spinal-Epidural Anesthesia on Ferroptosis, Humanin and MOTS-c Levels in Renal Transplantation
Platelet Reactivity, B-amyloid, MOTS-c and Mortality of Type II Diabetics With CAD
The Cardiovascular Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination
FDA recalls & enforcement
MOTS-c has no FDA recall or drug record at all — because it is not an FDA-regulated drug. That absence is not a safety signal. It means this compound is sold outside the system that inspects, tracks and recalls unsafe products in the first place.
Source: openFDA drug enforcement.
What people log it for
Descriptive, based on what users track. Not an endorsement or a suggested use.
Risks & unknowns
- No meaningful human safety or efficacy data.
- Gray-market purity varies.
Doses reported in studies & protocols
No established clinical dose. This is not a recommendation.
Purity reality
A COA is the only way to confirm content.
None yet. PLOBT does not publish invented purity numbers. Real third-party COA data, mapped to vendor and batch, is in development — and it is the one thing we refuse to fake.
Sources
We cite peer-reviewed journals, PubMed/PMC, FDA and university sources, not vendor marketing.